With investment into the Treg field at an all time high, excitement is overflowing at the prospect of these remarkable cells being game-changers in the long-term treatment of autoimmunity, inflammation and transplantation. As this enthusiasm coincides with multiple clinical readouts and several more therapies entering the clinic, it remains vital for Treg trailblazers to come together to recognize therapy efficacy, determine safety and translate the next-generation of therapies into the clinic.
With 3 jam-packed days of content across CAR-, TCR– and polyclonal Tregs as well as IL-2, muteins and small molecules, you won’t want to miss this unrivalled opportunity to collaborate with your peers in the Treg field to explore clinical advances, discuss challenges and discover next-gen methods to take Treg therapies to the next level.
Why Attend Now?
- Over $2 billion has been thrown into the Treg space in the past 8 months alone, reflecting the potential of these therapies
- 2022 saw the first-ever dosing of a human with a CAR-Treg cell therapy paving the way for the rest of the engineered Treg field
- Vital clinical updates determine the safety and efficacy of Treg modulating therapies
Secure your place today – https://ter.li/jddnbx